Literature DB >> 19217906

Trypanosoma cruzi: isolation and characterization of aspartyl proteases.

Rosa T Pinho1, Leila M Beltramini, Carlos R Alves, Salvatore G De-Simone.   

Abstract

Two aspartyl proteases activities were identified and isolated from Trypanosoma cruzi epimastigotes: cruzipsin-I (CZP-I) and cruzipsin-II (CZP-II). One was isolated from a soluble fraction (CZP-II) and the other was solubilized with 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate (CZP-I). The molecular mass of both proteases was estimated to be 120 kDa by HPLC gel filtration and the activity of the enzymes was detected in a doublet of bands (56 and 48 kDa) by substrate-sodium dodecyl sulphate-polyacrylamide-gelatin gel electrophoresis. Substrate specificity studies indicated that the enzymes consistently hydrolyze the cathepsin D substrate Phe-Ala-Ala-Phe (4-NO2)-Phe-Val-Leu-O4MP but failed to hydrolyze serine and other protease substrates. Both proteases activities were strongly inhibited by the classic inhibitor pepstatin-A (> or =68%) and the aspartic active site labeling agent, 1,2-epoxy-3-(phenyl-nitrophenoxy) propane (> or =80%). These findings show that both proteases are novel T. cruzi acidic proteases. The physiological function of these enzymes in T. cruzi has under investigation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19217906     DOI: 10.1016/j.exppara.2009.02.005

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  10 in total

1.  Cold-adapted digestive aspartic protease of the clawed lobsters Homarus americanus and Homarus gammarus: biochemical characterization.

Authors:  Liliana Rojo; Fernando García-Carreño; Maria de Los Angeles Navarrete del Toro
Journal:  Mar Biotechnol (NY)       Date:  2012-05-31       Impact factor: 3.619

2.  Multiple effects of pepstatin A on Trypanosoma cruzi epimastigote forms.

Authors:  Leandro S Sangenito; Keyla C Gonçalves; Erika A Abi-Chacra; Cátia L Sodré; Claudia M d'Avila-Levy; Marta H Branquinha; André L S Santos
Journal:  Parasitol Res       Date:  2011-12-29       Impact factor: 2.289

3.  Ddi1-like protein from Leishmania major is an active aspartyl proteinase.

Authors:  María J Perteguer; Paulino Gómez-Puertas; Carmen Cañavate; Francehuli Dagger; Teresa Gárate; Elizabeth Valdivieso
Journal:  Cell Stress Chaperones       Date:  2012-08-30       Impact factor: 3.667

4.  Inhibitory effects of pepstatin A and mefloquine on the growth of Babesia parasites.

Authors:  Tserendorj Munkhjargal; Mahmoud AbouLaila; Mohamad Alaa Terkawi; Thillaiampalam Sivakumar; Madoka Ichikawa; Batdorj Davaasuren; Tserendorj Nyamjargal; Naoaki Yokoyama; Ikuo Igarashi
Journal:  Am J Trop Med Hyg       Date:  2012-08-13       Impact factor: 2.345

5.  Why strategies to control Leishmania spp. multiplication based on the use of proteinase inhibitors should consider multiple targets and not only a single enzyme.

Authors:  Carlos Roberto Alves; Bernardo Acácio Santini Pereira; Mariana Silva-Almeida; Franklin Souza da Silva
Journal:  J Mol Model       Date:  2014-10-09       Impact factor: 1.810

6.  The major leucyl aminopeptidase of Trypanosoma cruzi (LAPTc) assembles into a homohexamer and belongs to the M17 family of metallopeptidases.

Authors:  Gloria Cadavid-Restrepo; Thiago S Gastardelo; Eric Faudry; Hugo de Almeida; Izabela M D Bastos; Raquel S Negreiros; Meire M Lima; Teresa C Assumpção; Keyla C Almeida; Michel Ragno; Christine Ebel; Bergmann M Ribeiro; Carlos R Felix; Jaime M Santana
Journal:  BMC Biochem       Date:  2011-08-23       Impact factor: 4.059

Review 7.  Aspartic peptidases of human pathogenic trypanosomatids: perspectives and trends for chemotherapy.

Authors:  L O Santos; A S Garcia-Gomes; M Catanho; C L Sodre; A L S Santos; M H Branquinha; C M d'Avila-Levy
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

8.  Decoding the anti-Trypanosoma cruzi action of HIV peptidase inhibitors using epimastigotes as a model.

Authors:  Leandro S Sangenito; Rubem F S Menna-Barreto; Claudia M D Avila-Levy; André L S Santos; Marta H Branquinha
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

9.  Repositioning drug strategy against Trypanosoma cruzi: lessons learned from HIV aspartyl peptidase inhibitors.

Authors:  Leandro Stefano Sangenito; Claudia Masini d'Avila-Levy; Marta Helena Branquinha; André Luis Souza Dos Santos
Journal:  Mem Inst Oswaldo Cruz       Date:  2022-03-16       Impact factor: 2.743

10.  Trypanosoma cruzi Presenilin-Like Transmembrane Aspartyl Protease: Characterization and Cellular Localization.

Authors:  Guilherme C Lechuga; Paloma Napoleão-Pêgo; Carolina C G Bottino; Rosa T Pinho; David W Provance-Jr; Salvatore G De-Simone
Journal:  Biomolecules       Date:  2020-11-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.